Rho GTPases are critical signal transducers of multiple pathways. They have been proposed to be useful anti-neoplastic targets for over two decades, especially in Ras-driven cancers. Until recently, however, few in vivo studies had been carried out to test this premise. Several recent mouse model studies have verified that Rac1, RhoA, and some of their effector proteins such as PAK and ROCK, are likely anti-cancer targets for treating K-Ras-driven tumours. Other seemingly contradictory studies have suggested that at least in certain instances inhibition of individual Rho GTPases may paradoxically result in pro-neoplastic effects. Significantly, both RhoA GTPase gain-and loss-of-function mutations have been discovered in primary leukemia/lymphoma and gastric cancer by human cancer genome sequencing efforts, suggesting both pro-and anti-neoplastic roles. In this review we summarize and integrate these unexpected findings and discuss the mechanistic implications in the design and application of Rho GTPase targeting strategies in future cancer therapies.
INTRODUCTION
Rho GTPases are a family of signalling proteins that belong to the Ras GTPase superfamily. 1 Mammalian Rho GTPases include 22 members, 2 of which the most-studied are RhoA, Rac1 and Cdc42. These proteins relay intracellular signals by acting as tightly regulated molecular switches (Figure 1a ). 3 The GTPase-activating proteins (GAPs) facilitate the slow intrinsic GTP-hydrolysis reaction to turn off signalling, while the guanine nucleotide exchange factors (GEFs) catalyse the GTP-loading reaction to turn on Rho GTPase signalling. An additional level of regulation is provided by Rho GDP dissociation inhibitors (GDIs), which bind to the GDPbound Rho GTPases, inhibiting GDP dissociation and sequestering them away from the active intracellular membrane sites. RhoGDIs can also prevent degradation of prenylated Rho GTPases when in the inactive state. 4 This dynamic cycle of GTP-loading/GTPhydrolysis is essential for proper Rho GTPase signalling function. Alterations of this process may result in changes in Rho GTPaseregulated cell functions including cell morphogenesis, adhesion, migration, cytokinesis, polarity, proliferation and survival ( Figure 1b ). 5 RhoA, Rac1 and Cdc42 are thought to be positively involved in cancer cell growth and potential anti-cancer targets in tumour initiation and metastasis. 6, 7 Evidence that they are pro-neoplastic emerged over 20 years ago with studies showing that constitutively active RhoA and Rac1 mutants possess weak transforming activity. [8] [9] [10] Dominant negative forms of Rho GTPases could block K-Ras or other oncogene-driven transformation of fibroblasts, suggesting an interconnection between Rho and Ras signalling pathways. Additional evidence for Rho and Ras crosstalk includes that RhoA or Rac1 could transform fibroblasts synergistically with oncogenic Raf 8 and a shared connection between RhoA and Ras with serum response factors 11 that bind to serum response elements and induce the expression of genes important for cell cycle progression, growth, division and differentiation. A number of Ras effector pathways had been found to lead to Rho GTPase activation. 12, 13 For example, Ras binds to and activates T-lymphoma invasion and metastasis-inducing protein 1 (TIAM1), a GEF for Rac1 that may activate Rac1 to contribute to Ras transformation. 14 PI3Ks , one of the main effector pathways of Ras, can also activate Rac1 via the PIP 3 -dependent Rac Exchanger (P-Rex) family of Rac GEFs. 15 Although tremendous efforts have been dedicated to further implicating individual Rho GTPases in subsequent studies, [16] [17] [18] [19] [20] limited information from primary human cancers or mouse cancer model studies was available until recently. Several key findings came to light in the past several years yielding more complicated implications related to the role of individual Rho GTPases in several cancer types. In parallel, small molecule targeting of Rho GTPases has progressed in preclinical studies, making available lead chemical probes that have translational values. It is thus timely to review recent findings of Rho GTPase signalling in cancer biology, and refresh the implications in rational targeting of Rho pathways in neoplasia.
RHO GTPASES AS PRO-ONCOGENIC SIGNAL TRANSDUCERS
Rho GTPases and signalling molecules that activate their activitysuch as GEFshave traditionally been considered as oncogenic, and therefore potential anti-neoplastic targets. [21] [22] [23] Indeed, in the past two decades, numerous studies have demonstrated the roles of multiple Rho GTPases in tumorigenesis. Much of the earlier work used loss-or gain-of-function mutant Rho GTPase overexpression in cancer cell or fibroblast cell lines in vitro, and the results supported the pro-proliferation and pro-metastasis functions of RhoA, Rac1 and Cdc42. In agreement with this, overexpression or hyper-activation of many Rho GTPases have been implicated in various human cancers and have been extensively reviewed elsewhere. 24, 25 Recent cancer genetic studies by whole-genome sequencing have identified a growing list of recurrent mutations in Rho GTPases (reviewed in Porter et al. 25 , Alan et al. 26 ), which were previously thought to be rare. Further, an intimate involvement of Rho GTPases in modulating multiple cell types in the tumour microenvironment, which have active roles in angiogenesis, chemotaxis and inflammatory responses, also strongly implicates their pro-neoplastic roles. 7, 27 Adding to the understanding of Rho GTPase signalling pathways and functions characterized by biochemical and cell biological approaches, in vivo cell-type specific and cancer-type specific functions of mammalian Rho GTPases have been delineated recently by murine conditional-knockout genetic models, [28] [29] [30] including in Ras-driven cancer models (Table 1) . These mouse genetic models and human cancer genetic findings of 'hot-spot' mutations of Rho GTPases further invigorate the interests.
RhoA A previous Drosophila study by a forward genetic screen had identified genes that cooperate with oncogenic Ras to drive eye hyperplasia/tumorigenesis. 31 Interestingly, many positive hits in the screen belonged to the Rho GTPase pathway including Rho1, Rac1 and RhoGEF2, which all enhanced Ras-driven tumorigenesis in a JNK-dependent manner. The positive influence of RhoA in cancer was strengthened by two recent reports exploring therapeutic targets in K-Ras-driven murine models of lung cancer. The first report found that K-Ras-mutant cancer cells, but not K-Ras wild-type cancer cells, were vulnerable to perturbations in a GATA2 regulated set of signalling pathways including Rho signalling, IL-1/NF-κB signalling and Nrf1/proteasome function. 32 Using a mutant K-Ras non-small cell lung cancer mouse model, the authors further showed that the adenomas could be induced to regress by combination treatment with proteasome and Rho signalling inhibitors. In the second paper, study of a lung adenocarcinoma model in mutant K-Ras; Cdkn2a-null mice found that RhoA signalling was upregulated in adenocarcinomas and downstream focal adhesion kinase (FAK) was a key for malignant phenotypes in both lung adenocarcinoma cell lines as well as in a mouse model. 33 Additionally, studies of RhoA contribution to gastric cancer implicate RhoA activity as a permissive signal for G1-S-transition of the cell cycle progression through INK4 family members. 34 Recent human cancer genetic studies utilizing whole genome sequencing have found recurrent RhoA mutations in gastric cancer, [35] [36] [37] [38] peripheral T-cell lymphoma (PTCL), [39] [40] [41] [42] adult T-cell leukemia/lymphoma (ATLL), 43 Burkitt lymphoma (BL), 44 and head and neck cancer. 45 Some of them appear to be gain-of-function while a significant portion are loss-of-function, and their functional significance has yet to be causally defined. Consistent with a procancer progression role, duplication of exons in ROCK, a RhoA effector, presumably resulting in a gain-of-function, has also been described in lung adenocarcinoma. 46 
RhoC
RhoC has long been associated with cancer cell invasion and metastasis. 18 The first mouse model to address the role of RhoC in metastasis in vivo was that of Hakem and colleagues where they produced a constitutively RhoC-null mouse that, surprisingly, showed no abnormal phenotype at its basal state. 47 To assess the effect of RhoC on metastasis, the authors used the MMTV-PyVT transgenic mouse (Mouse Mammary Tumour Virus (MMTV) -driven Polyoma Virus middle T antigen (PyVT)), which developed mammary tumours that metastasized to the lung with high penetrance. In this genetic background, RhoC loss led to dramatically fewer metastases to the lung, and the resulting mammary tumour cells showed reduced invasion activity in vitro. This evidence correlates with clinical observations of elevated RhoC levels associated with metastatic grade in human breast and gastric cancers. 48, 49 Rac1 and Cdc42 Both Rac1 and Cdc42 were shown to be pro-transformation in early fibroblast studies. Rac1 conditional knockout mouse studies have shown that Rac1 is necessary for K-Ras-driven lung adenoma formation, 50 epidermal papilloma initiation and growth, 51 and dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumour formation. 52 In a K-Rasdriven pancreatic ductal adenocarcinoma mouse model, pancreasspecific disruption of Rac1 or p110α, but not p110β, prevented the development of pancreatic tumours, and the loss of transformation was independent of protein kinase B (PKB, also known as AKT) regulation. 53 In a retroviral expression model of MLL-AF9 induced leukemogenesis, Rac2, but not Rac1, is critical to the initiation of acute myeloid leukemia. However, loss of either Rac1 or Rac2 is sufficient to impair survival and growth of the transformed MLL-AF9 leukemia. 54 Induced deletion of Rac1 in endothelial cells suggested that Rac1 is required for embryonic vascular integrity and angiogenesis, representing potential anti-angiogenetic therapeutic targets for cancer. 55 In a mouse model for benign, more differentiated sebaceous skin tumours, epidermis-specific Rac1 activity did not alter tumour incidence and frequency, but suppressed tumour cell differentiation leading to malignant progression of sebaceous tumours. 56 Likewise, conditional deletion of Cdc42 in Ras-transformed fibroblast cells drastically alters cell morphology and inhibits proliferation, cell-cycle progression and tumorigenicity. 57 In a mouse colorectal cancer model, Cdc42 ablation suppressed the malignant progression of early-stage intestinal epithelial cancer cells carrying single APC or betacatenin mutations. 58 Rac1 and Cdc42 protein levels have been shown to be upregulated in multiple human cancers. Rac1b, the splice variant of Rac1 that contains a 19 amino acid insert adjacent to the switch II domain resulting in increased signalling and ROS generation, has emerged as a variant that is upregulated in several cancers such as lung, breast, colon and thyroid cancers. 48, [59] [60] [61] [62] Also, Rac1b may cooperate with B-Raf oncogenic mutant V600E in promoting tumorigenesis. 61, 63 In a mouse model of K-Ras induced lung adenocarcinoma, expression of Rac1b synergized with oncogenic K-Ras and caused increased proliferation and accelerated tumour growth. 64 Recent cancer genome sequencing efforts have revealed functionally relevant Rac1 gain-of-function mutations. Two studies utilizing whole genome sequencing of over 120 melanoma samples found a frequent and previously undescribed Rac1 mutation: 5% of melanomas 65 and 9.2% of sun-exposed melanomas 66 contain a recurrent Rac1 P29S mutation that increases its GTP-bound active state and binding to effector proteins with enhanced signalling. A similar mutation, P29L, was found in Rac2. 65 Additional activating Rac1 mutations A159V and Q61R were later found in head and neck cancer and prostate cancer, respectively. 67 GEFs and effectors Historically, the positive Rho GTPase regulators, GEFs and Rho effectors are considered pro-oncogenic and pro-growth, whereas negative regulators such as Rho GAPs are considered tumour suppressing. For instance, the Rac GEF TIAM1 is also a potential effector for H-and K-Ras, and both its upregulation and deletion have been implicated in tumour initiation and metastasis, respectively (reviewed in Cook et al. 22 ). Another Rac GEF, PREX2, is found to be mutated in human melanoma, 68 pancreatic cancer 69 and colorectal cancer. 70 Certain PREX2 mutations, when expressed in murine melanoma models, increased Rac1 activity, PI3K-AKT pathway signalling and tumorigenesis, along with shortened survival life of the mice. 71 Vav1, a normally hematopoietic cell-specific RhoGEF, has been identified to be mutated in ATLL 72 and lung adenocarcinoma, 73 and found to be involved in novel fusions in PTCLs. 74 An analysis of the genome data set by Kakiuchi et al 35 using CHASM 75 identified a possible driver mutation in ArfGEF1 in gastric cancer. 76 Mutations in DOCK2 and DOCK3, which belong to a different family of Rho GEFs from the Dbl-like molecules, have also been identified recently in colorectal cancer. 70 Interestingly, certain functions of RhoGEFs in tumours could be independent of their nucleotide exchange activity. For example, P-Rex2a can act as a component of the PI3K pathway by interacting with PTEN to suppress its lipid phosphatase activity in tumour cells. 77 GEF-H1, a RhoA GEF, is a critical part of a positive feedback loop in the Ras pathway via direct interaction with scaffolding protein Kinase suppressor of Ras 1 (KSR-1). 78 With regard to effector proteins, abrogation of ROCK signalling has been shown to have a mortality benefit in murine models of leukemia, hepatocellular carcinoma, as well as breast and lung carcinomas. [79] [80] [81] Deletion of both ROCK isoforms, Rock1 and Rock2, but not individually, blocked tumour formation in mouse models of non-small cell lung cancer and melanoma, suggesting indispensable yet redundant roles for ROCK1/2 in cell cycle progression and tumorigenesis. 82 ROCK inhibitors may have high potential for treating cancer and other physiological conditions, and they are being investigated in clinical trials for human diseases including solid tumours. 83 While multiple ROCK inhibitors target the ATP binding pocket, classic inhibitors such as fasudil and Y27632 are generally not ROCK isoform selective and also interfere with other AGC kinases such as protein kinase N (PKN) kinases (also known as PRKs), another effector of Rho, with slightly lower potency. 84 Considerable efforts are being devoted to developing new ROCK inhibitors with higher potency and selectivity. 81 Studies of other downstream proteins such as RhoA effector formins have yielded positive results with regard to inhibiting cancer cell motility and progression. 85 Both Rac1 and Cdc42 directly bind to and activate p110β, a subunit of PI3K, via the Rho binding domain of p110β. 86, 87 The Rac1/Cdc42 effector PAK family kinases (p21-activated kinase), known to phosphorylate important cell signalling proteins such as Bcl-2, MEK, and Raf1 and is a part of the MAPK, JNK and NF-κB pathways, have been found to be upregulated in human cancers. 88 Deletion of PAK1 led to a dramatically reduced tumorigenesis and tumour progression in a K-Ras-induced skin cancer model, 89 and inhibition of PAK1 attenuated tumour growth and metastasis in a model of pancreatic adenocarcinoma. 90 These crucial effector pathways of Rho GTPases appear consistently involved in pro-oncogenic signalling.
RHO GTPASES WITH POTENTIAL TUMOUR SUPPRESSING ROLES While most Rho GTPases, especially RhoA, Rac1 and Cdc42, along with their signalling components, have been considered proneoplastic (exceptions include RhoB, 91 RhoE 92 and RhoH 93 ), recent mouse model and human genomic data have emerged to suggest that RhoA, Rac1 and Cdc42 can also act in a tumour suppressing role under defined conditions. This new information (Table 1; Figure 2 ) raises the question whether individual Rho GTPases are pro-or anti-neoplastic in a given tumour, and sheds new light into therapeutic targeting strategies of Rho pathways.
RhoA A recent study of K-Ras-induced hepatic adenoma formation in Zebra fish found that constitutively active RhoA reduced adenoma size and increased animal survival, while dominant negative RhoA resulted in larger adenomas and decreased survival. 94 These observations appear opposite of results from in vitro studies of K-Ras transformed fibroblasts by dominant RhoA mutant expression. The authors found that increased neoplasia resulting from dominant negative RhoA was in part due to increased AKT and S6 signalling and upregulation of cyclin D1. This finding is in line with two in vitro studies that found RhoA negatively regulated AKT phosphorylation and decreased cyclin D1 levels in endothelial cells and K-Ras-driven adrenocortical cancer cell lines. 95, 96 Another recent study of a murine colon cancer model induced by mutant APC found that simultaneous expression of dominant negative RhoA resulted in larger and more frequent adenomas and decreased survival. 97 Perhaps more intriguing, conditional gene deletion of either RhoA or RhoC alone did not suppress K-Ras G12Dinduced lung adenoma initiation. Rather, deletion of RhoA alone exacerbated lung adenoma formation, whereas dual deletion of both RhoA and RhoC significantly reduced K-Ras G12D -induced adenoma formation. 98 In this context, deletion of RhoA seems to induce a compensatory mechanism that exacerbates adenoma formation, which is at least partly mediated by RhoC.
The strongest evidence that RhoA may have a tumour suppressor role has come to light in human cancer genomic studies (Figure 2 ; commented in refs [99] [100] [101] [102] [103] . A compelling finding is the recent whole exome sequencing of T-cell lymphoma in several studies, which found that 50.3-70.8% of angioimmunoblastic T-cell lymphoma and 7.7-18% of PTCL, not otherwise specified (PTCL-NOS), share a recurrent RhoA G17V mutation. RhoA G17V causes a loss of nucleotide binding, enhanced GEF interaction, and may act as a dominant negative. [39] [40] [41] [42] Another study of Burkitt lymphoma in children found recurrent RhoA mutations such as RhoA R5Q , which appear to be loss-of-function and predominately disrupt RhoA interactions with GEFs. 44 Further characterization of RhoA R5Q mutation confirmed its impaired activity using biochemical and cell functional assays. 104 Most recently, a study of ATLL found that~15% of ATLLs have several recurrent RhoA mutations in the GTP binding pocket, some of which were previously undescribed. 43 Interestingly, some of the recurrent mutations are gain-of-function mutations, while others are loss-of-function or even dominant-negative mutations. These genetic data indicate that both gain-and loss-of-function RhoA mutations may be pro-oncogenic depending on the cell of origin of the ATLL, such that gain-of-function RhoA mutations are prooncogenic in Tregs, whereas loss-of-function mutations are prooncogenic in T memory cells.
Inactivating RhoA mutations have also been found in solid tumours. A large scale human cancer genetic study of paired normal and tumour tissues across multiple cancer types identified recurrent RhoA mutations at E40 or Y42 in seven tumours (six head and neck, one breast) that are likely to disrupt the interaction of RhoA with effectors. 45 Similar mutations thought to abrogate or modulate RhoA effector interactions have been recently described in gastric cancer. [35] [36] [37] [38] RhoA mutation prevalence was estimated at 14.3-25.3% in diffuse-type gastric cancer and 3.9-5.4% in the whole cohort. RhoA mutations were noted in hotspot sites including Y42, G17, L57 and R5 (Figure 2 ). SiRNA-knocking down of RhoA in gastric cell lines containing mutant RhoA in Y42 or G17, but not wild-type RhoA, significantly impairs proliferation. 35 Further rescue experiments in cells suggested that Y42C and G17E are gain-of-function mutations that may provide a strong growth advantage. 35 However, biochemical analysis showed that Y42C and L57V are reduced in the active form, suggesting they work in a loss-of-function manner. 36 Indeed, RhoA Y42C has been evaluated in earlier biochemical assays and shown attenuated activation of PKN, but not mDia2 and ROCK1. 105 Most recently, by applying an unsupervised method, ParsSNP, to the gastric cancer genome data set from Kakiuchi et al, 35 Kumar et al confirmed that RhoA Y42C may be a driver mutation. 76 Recent studies of Gα 13 -RhoA signalling axis with a tumour suppressor role in Burkitt's lymphoma and diffuse large B-cell lymphoma have begun to causally associate the loss of RhoA signalling with tumorigenesis. 92 It will be important to better define the mechanism of loss-offunction RhoA mutants, to contrast with gain-of-function mutants.
RhoB and other Rho family members
In contrast to findings suggestive of increased RhoA and/or RhoC expression or activity in many cancers, it has been long known that RhoB is deleted in multiple cancers, including lung cancer. [106] [107] [108] Although RhoA, B and C can all regulate actin stress fibres, cytoskeleton organization and vesicle transportation redundantly, RhoB differs from RhoA/C in cellular localization and has distinct functions. RhoB is primarily localized to endosomes and regulates cytokine trafficking and cell survival, 109 and has antiproliferative and pro-apoptotic effects in cancer cells. 91 RhoB is unique in that it can be modified by either a farnesyl or a geranylgeranyl moity, and its prenylation state seems to affect RhoB actions. Whereas farnesylated RhoB can be either pro-or anti-growth in different settings, geranylgeranylated RhoB displays consistent anti-growth activity. 110 RhoB appears to act more than an inhibitory isoform that opposes the effects of RhoA and RhoC signalling. 110 In agreement with its tumour suppressor role, RhoB deletion was shown to accelerate chemically induced skin tumours in mice. 111 In a recent study, RhoB deletion lowered the risk of Ultraviolet B (UVB)-induced skin carcinogenesis, but tumours that did form were preferentially undifferentiated and highly proliferative, suggesting RhoB may promote skin cancer initiation but limits the tumour aggressiveness. 112 There is evidence that Cdc42, which is typically considered an oncoprotein, can also present a tumour suppressing function as exemplified by the finding that mice with Cdc42 deficiency in blood developed a lethal myeloproliferative disorder. 113 Likewise, mouse with Cdc42 ablated in hepatocytes and bile duct cells developed hepatomegaly soon after birth, and signs of transformation and hepatocellular carcinoma was observed later. 114 Intestinal deletion of Cdc42 resulted in a hyperplasia of intestinal 39 RhoA mutations other than G17V were identified in a single case each and the authors did not specify the PTCL subtype. They are included in PTCL-NOS here for simplicity. epithelial cells and drastically increased intestine length and thickness. 115 Recently, Rac1 and Cdc42 activities were found to be decreased in human pheochromocytomas, possibly resulting from reduced expression level of two RhoGEFs, ARHGEF1 and FARP1. 116 GAPs and other Rho GTPase regulators Since Rho GAPs act to decrease Rho-GTP species, they are generally considered tumour suppressors by virtue of their capability to downregulate Rho/Rac/Cdc42 activities. 117 For instance, DLC-1 gene, the product of which is a Rac GAP, so named because it is often deleted in liver cancer, is either deleted or methylated in a wide variety of cancers. 118, 119 However, another GAP that regulates RhoA activity, p190GAP, has been found to have upregulated in expression in inflammatory breast cells, and may have a pro-growth role. 120 P190B heterozygous mouse showed reduced tumour penetrance and remarkably delayed tumour onset in MMTV-Neu breast cancer model. 121 Similarly, expression of several RhoGAP genes was increased in basal-like breast cancer, and knockdown of two of them, ArhGAP11A and RacGAP1, resulted in significant defects in the proliferations of basal-like breast cancer cells. 122 In the same study using CHASM 75 to analyse the data set from Kakiuchi et al, 35 a potential driver mutation in one RhoGAP, ArhGAP28, was identified. 76 While the role of individual RhoGAP in specific cancer awaits further characterization, their apparent pro-and anti-cancer cell proliferative functions may be associated with the paradoxical role of their respective substrates, Rho GTPases. Alternatively, RhoGAPs may be associated with the cycling regulation of Rho GTPases. Overexpression of RhoGAPs may allow proper cycling of Rho GTPase substrates under conditions of exacerbated Rhodependent signalling in cancer cells.
Changes of RhoGDIs expression levels have also been associated with cancer. 123 The changes vary by cancer types (reviewed in Garcia-Mata et al. 124 ). For example, RhoGDI1 expression is upregulated in colorectal and ovarian cancers, [125] [126] [127] but downregulated in brain cancers. 128 Increased expression of RhoGDI2 has been found in pancreatic cancers, 129, 130 while the opposite occurs in bladder cancers. 131 In breast cancer, conflicting results have been found for RhoGDI1 expression, 48, 132 whereas GDI2 seemed to have a biphasic expression pattern. 133 Genetic studies of specific RhoGDI in murine cancer models have been lacking and the full degree of complexity of RhoGDI function and regulation in cancer remains to be appreciated.
BALANCING THE PRO-AND ANTI-NEOPLASTIC ROLES OF RHO GTPASES IN DEVELOPING TARGETED THERAPY
An outstanding question is how to reconcile the pro-and antineoplastic effects attributable to individual Rho GTPases. While the majority of in vitro studies examining the role of RhoA, Cdc42 and Rac1 support their pro-neoplastic function, it is within the mouse in vivo and human genetic findings where the opposite effects arise. How can we reconcile such seemingly paradoxical findings? This may be partly explained by the difference between in vitro and in vivo experimental systems. First, in vitro studies may be biased due to extensive culture resulting in clonal variability of cell lines. The cell lines are well adapted towards rapid growth with reliance on key signalling pathways including Rho GTPases, and could be hypersensitive to perturbations of key signal transduction pathways. In contrast, malignant cells in an in vivo environment may be more resilient to cell signalling perturbations and possess a malleable signalling network more plastic for adaptive compensations. Second, Rho GTPases may also affect the tumour microenvironment in vivo, which is missing in vitro, to either favour or antagonize tumour growth in a cell-type specific manner. Third, manipulating the level of one Rho GTPase in cell lines may affect the level and activity of other endogenous Rho GTPases, thereby, some of the conclusions from in vitro studies need to be cautioned. It is increasingly clear that our current understanding of Rho signalling in tumorigenicity is still incomplete.
Analogy to other targeted approaches in compensatory response In a recent study, RhoA was found to be pro-neoplastic in the absence of RhoC, but anti-neoplastic in the presence of RhoC in murine lung adenoma model. 98 This seemingly paradoxical observation shares an analogy with other targeted therapy situations. A prominent example is the adverse effects of B-Raf inhibitors. 134 Despite the well-appreciated pro-neoplastic role of BRAF-activating mutations in metastatic melanoma, clinical trials of the B-Raf inhibitors, vemurafenib and dabrafenib, yielded unexpected results that B-Raf targeting can mediate the related C-Raf activation leading to a relapse of more malignant tumours. 135, 136 This compensatory interplay of B-Raf and C-Raf parallels that of Rho GTPase crosstalk, including the roles of RhoA and RhoC, despite that they may be mediated by distinct mechanisms (Figure 3) . Such a compensatory response is not surprising in the context of cancer cell signalling network. In a recently report, inhibition of MEK in K-Ras-mutant lung and pancreatic cancer cells provokes a signalling rebound via FGFR1. Combinational inhibitors of MEK and FGFR1 enhance tumour death in vitro and in vivo. 137 The compensatory response may reflect another way that Rho family members can contribute to the development of resistance to targeted therapies: the level or activity of one Rho protein can affect the level and/or activity of others.
Rational targeting of Rho GTPase signalling Due to their globular structure, small GTPases such as Rho and Ras have been deemed 'undruggable' by traditional drug design approaches. However, there have been advances in the field over the past decade with pre-clinical and clinical progress of several targeting strategies of Rho GTPase pathways. One strategy is targeting the interaction of Rho GTPase with its GEFs, which has been achieved at the preclinical level in the three prototypical Rho GTPases, that is Rac1, RhoA and Cdc42. For example, NSC23766 is an inhibitor that disrupts the interaction of Rac1 with GEFs such as TIAM1, and CASIN is a Cdc42 inhibitor that disrupts the Rho:GEF Figure 3 . A scheme of the interplay between RhoA and RhoC signalling in K-Ras-driven cancer. The model summarizes the possible effects of RhoA inhibition on K-Ras-driven tumour formation. RhoA loss can paradoxically result in increased oncogenesis through a compensatory elevated RhoC activity, endowing RhoA to behave in a tumour suppressing role. In the absence of RhoC, RhoA is required for oncogenesis, displaying pro-oncogenic signal as an antineoplastic drug target.
interaction. 138, 139 In fact, Rac1 inhibitors are especially desirable in the treatment of many melanomas, as common Rac1 P29S mutation in melanoma has been shown to confer resistance to B-Raf inhibitors for the treatment of B-Raf-driven metastatic melanomas. 140 The chemical probe Rhosin (also termed G04) was developed to bind between the two important 'switch' regions of RhoA and inhibit its interaction with GEFs such as leukemia-associated RhoGEF (LARG). Not only does this probe decrease phosphorylation of myosin and have antineoplastic effects in vitro, but importantly it inhibits signalling of RhoC as well. 141, 142 The alternate approach of targeting RhoGEFs rather than Rho GTPase itself has also been useful conceptually for inhibiting Rho activities. For example, the chemical probe Y16 binds to LARG and inhibits Rho GEF activity. 141, 143 The other major target for disrupting GTPase activity is the activity of downstream effectors. With regard to Rho GTPases, a successful example is the ROCK inhibitors fasudil and Y-27632. 144, 145 Both inhibitors bind the ATP-binding pocket of ROCK and inhibit serine-threonine kinase activity. Fasudil is the only clinically used Rho GTPase pathway inhibitor and is used to treat pulmonary hypertension and cerebral hypertension in Japan, along with a sister compound, ripasudil, being used to treat glaucoma in Japan. Other GTPase effector inhibitors include several developed against the Cdc42 and Rac effector, PAK. 146 Another notable lead inhibitor, Phox-I, inhibits the Rac effector p67 phox of the NOX2 enzyme complex, which produces Rac-mediated superoxide. 147 Extensive reviews can be found elsewhere describing the development of Rho GTPase inhibitors and strategies to inhibit GTPase signalling including targeting GDIs or post-transcriptional modifications. 24, 148, 149 Despite the important roles of Rho GTPases in cancer and considerable efforts to target Rho-dependent pathways, no inhibitor of Rho GTPase signalling has yet been used clinically to treat cancer, and the number of clinical trials is still limited. Besides the technical difficulty to target small GTPases per se, one major challenge is the lack of knowledge about the actual roles of Rho GTPase-dependent pathways at the organismal level, which is reflected by the recent human cancer genetic studies. It will be important to carry out further analysis of the signalling network changes of the gain-and loss-function mutation bearing tumours, particularly the downstream pathways that may better explain possible compensatory effects and selection pressure of the cancer cells under the driver mutations and defined microenvironment. Such comprehensive characterization of Rho GTPase signalling activities will guide the rationale in pharmacological targeting of Rho GTPases for anti-cancer therapy development.
In addition to modulate cancer cell proliferation, survival and migration, Rho GTPase pathways play a role in the resistance of anti-cancer radiotherapy and chemotherapy. For example, the RhoA/ROCK pathway was implicated in cancer cell stemness and radioresistance. 150 Overexpression of RhoGDI1 increased resistance of cancer cells to the induction of apoptosis by chemotherapeutic agents etoposide and doxorubicin, 151 and RhoGDI2 was identified as a key player in resistance to a cyclin-dependent kinases inhibitor. 152 Thus, combined inhibition of Rho signalling with other anti-cancer therapy may be useful to achieve greater efficacy while reducing potential resistance. To this end, ROCK inhibitor fasudil and MEK inhibitor trametinib cooperatively induced apoptosis in N-Ras mutant melanoma. 153 Using a synthetic lethal drug screen to identify innovative drug combinations to treat K-Ras mutant cancers, Wang et al recently showed that dual inhibition of Rho signalling components polo-like kinase 1 (PLK1) and ROCK leads to synergistic effects to induce apoptosis and cell-cycle arrest in vitro and causing potent tumour regressions in vivo. 154 
CONCLUSIONS AND PERSPECTIVES
Rho GTPase signalling is important in Ras pathways and other cancer-driven mechanisms. Multiple Rho GTPases have been found to be potential anti-neoplastic targets in a wide variety of cancers including colon cancer, breast cancer and leukemia. 7, 155, 156 Fasudil, a ROCK inhibitor, has been used to treat pulmonary hypertension and is now being researched for the treatment of refractory angina. [157] [158] [159] Recent studies show that Rho GTPases, RhoA and Cdc42 in particular, may also behave as 'tumour suppressors' in certain cancer and defined circumstances. Such a complex, and sometimes paradoxical, interpretation of Rho GTPase functions also applies to their regulators and effectors, and redundant functions between Rho family homologues and interplays of feedback signalling loops may be involved. Dynamic selection pressure upon loss or gain of a Rho GTPase function is likely a contributing factor in the specific tumour context, as evidenced in T-cell leukemia and lymphoma. 43 Loss-and gain-offunction mutations of RhoA may endow the tumour cells selective advantage in early vs late stages of the cancer progression, respectively. Further stringent demonstrations of their causal role and unveiling the underlying mechanism in driving tumorigenesis or tumour suppression in specific cancer types are warranted.
Considering recent findings, development of novel approaches inhibiting individual Rho GTPase activities need a more careful consideration. The timing and balance of downstream signals and possible compensatory feedback mechanisms after effective inhibition of one Rho GTPase must be assessed in order to ensure a beneficial tumour suppressing outcome. For example, the possible redundant and compensatory signalling from RhoC should be considered upon specific targeting of RhoA in tumours from the onset. These considerations suggest that the use of relatively more 'promiscuous' drugs that inhibit multiple Rho GTPases such as RhoA/RhoC or further downstream signalling, such as ROCK or PAK, with acceptable toxicity, may provide better efficacies and also be beneficial for reducing potential resistance to the therapy against a single Rho GTPase target. In congruence with this idea, agents such as phytochemical rocaglamide that inhibits the activities of Rho, Cdc42 and Rac 160 may represent a new class of anticancer drugs. Although inhibitors of Rho GTPase pathways have not been clinically used for cancer treatment, rational targeting of Rho GTPase signalling nevertheless carries significant potentials in anti-cancer drug discovery, especially in future combinatory therapies.
